AB Science

ABFR0010557264

RSS feed

Filings

95 filings

All Inside information95 Annual financial report4 Earnings release3 Half-year financial report1

10/07/2026
AB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programs
Inside informationFR
07/07/2026
Nomination de Stéphane LEDERMANN en qualité de Président Directeur Général
Inside informationFrench
01/07/2026
AB Science : Résultats de l'Assemblée Générale Mixte du 30 juin 2026
Inside informationFrench
01/07/2026
AB Science announces the successful completion of a EUR 2.3 million private placement
Inside informationFR
29/06/2026
AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML
Inside informationFR
17/06/2026
AB Science patent for masitinib in the treatment of metastatic castrate resistant prostate cancer formally granted in the United States with a protection until 2042
Inside informationFR
09/06/2026
AB Science is invited to present at the 2026 ENCALS annual meeting the survival data from masitinib clinical program in ALS
Inside informationFR
02/06/2026
AB Science : Stonegate Capital Partners updates its coverage of AB Science’s stock with a target price of EUR 4.25 per share
Inside informationFR
25/05/2026
AB Science announces that its stock continues to be covered by Maxim Group, with a target price of €4.00 per share
Inside informationFR
13/05/2026
AB Science reports its revenues for the year 2025 and provides an update on its activities
Inside information
29/04/2026
AB Science announces the successful completion of a EUR 3.2 million private placement
Inside informationFR
27/04/2026
AB Science announces a final agreement on the renegotiation of the repayment terms of its loans with all of its financial creditors
Inside informationFR
20/04/2026
AB Science: New publication on medrxiv demonstrating substantial survival benefits and preserved quality of life with masitinib in ALS patients
Inside informationFR
16/04/2026
AB Science provides an update on its clinical development program.
Inside informationFR
24/02/2026
AB Science announces the identification of a plasma biomarker that indicates the activity of masitinib in treating ALS
Inside informationFR
09/02/2026
AB Science announced that the Food and Drug Administration (FDA) granted the status of Minor Use in Major Species (MUMS) for Masivet® in the treatment of canine mast cell tumors
Inside informationFR
29/01/2026
AB Science receives notice of allowance for US patent covering masitinib in the treatment of metastatic castrate resistant prostate cancer
Inside informationFR
21/01/2026
AB Science receives Japanese patent protection for the use of masitinib in progressive forms of multiple sclerosis (MS) until 2041
Inside informationFR
07/01/2026
AB Science reports fourth consecutive case of response from Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia
Inside informationFR
22/12/2025
AB Science patent for masitinib in the treatment of sickle cell disease formally granted in the US with a protection until 2040
Inside informationFR
18/12/2025
AB Science announces the initiation of coverage of its stock by Maxim Group with a target price of EUR 4.0 per share
Inside informationFR
15/12/2025
AB Science announces a new publication on biorxiv that identifies AB8939 as a promising drug candidate for treating refractory acute myeloid leukemia and potentially other cancers
Inside informationFR
11/12/2025
AB Science announces new publication on Medrxiv highlighting clinical benefit with masitinib in Amyotrophic Lateral Sclerosis patients prior any complete loss of function
Inside informationFR
17/10/2025
AB Science announces the successful completion of a EUR 2.8 million private placement
Inside informationFR
16/10/2025
AB Science provides intitial Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia
Inside informationFR
14/10/2025
AB Science will hold a virtual conference on Thursday, October 16, 2025 from 2pm to 3pm CET to provide an update on the Phase 1 study with AB8939
Inside informationFR
10/10/2025
AB Science today reports its revenues for the first half of 2025 and provides an update on its activities
Inside information
30/09/2025
AB Science announces a slight delay in the publication of its 2025 half-year financial report
Inside informationFR
04/08/2025
AB Science announces the successful completion of a 2.55 million euros private placement
Inside informationFR
30/07/2025
AB Science receives regulatory approval from European countries to initiate third stage of Phase I/II study combining its molecule AB8939 with venetoclax for the treatment of AML
Inside informationFR
24/07/2025
AB Science has received approval from several European countries to initiate the confirmatory phase 3 study of masitinib in ALS
Inside informationFR
08/07/2025
AB Science announces the successful completion of a EUR 1.925 million private placement
Inside informationFR
04/07/2025
AB Science : Le masitinib reçoit l'autorisation de la FDA et de l'EMA pour l’etude confirmatoire de phase 3 dans le cancer de la prostate métastatique hormono-resistant
Inside informationFrench
01/07/2025
AB Science : Résultats de l'Assemblée Générale Mixte du 30 juin 2025
Inside informationFrench
30/06/2025
AB Science provides an update on the renegotiation of loan repayment terms with its financial creditors
Inside informationFR
23/06/2025
AB Science - New peer-reviewed data provide strong evidence supporting masitinib potential for the treatment of Alzheimer’s disease
Inside informationFR
12/06/2025
AB Science announces issuance of a Canadian patent protecting the composition of matter of AB8939, including its use in the treatment of acute myeloid leukemia, with protection until 2036
Inside informationFR
09/06/2025
AB Science announces EMA approval of Masivet shelf-life extension to 4 years
Inside informationFR
23/05/2025
AB Science announces the settlement delivery of its latest capital increase for €1.8 million
Inside informationFR
20/05/2025
AB Science announces the successful completion of a EUR 1.8 million private placement
Inside informationFR
19/05/2025
AB Science receives Chinese patent protecting masitinib in the treatment of Covid-19 until 2041, adding one more indication with long term intellectual property protection
Inside informationFR
15/05/2025
AB Science today reports a new publication in the scientific journal PLOS One, showing promising neuroprotective effects of masitinib
Inside informationFR
12/05/2025
AB Science reports its revenues for the year 2024 and provides an update on its activities
Inside information
05/05/2025
AB Science will present new data from masitinib clinical program in ALS in two presentations at the 2025 ENCALS Annual Meeting
Inside information

About

ISIN: FR0010557264
Ticker: AB
LEI: 969500U43TVR8CCVBJ97
Country of registration: FR
Last filing: 10/07/2026, 17:49

Sparse profile

The AMF publishes neither sector nor description. These fields are enriched from Wikidata where a match exists.

Filing history

Filings per month

Sept 23May 24Jan 25Sept 25Aug 26

Document types

Across the whole archive